A Study of Tisotumab Vedotin for Patients With Platinum-Resistant Ovarian Cancer With a Safety Run-in of a Dose-Dense Regimen (innovaTV 208)



Status:Recruiting
Conditions:Ovarian Cancer, Cancer, Cancer, Cancer, Cancer, Cancer
Therapuetic Areas:Oncology
Healthy:No
Age Range:18 - Any
Updated:4/4/2019
Start Date:March 2019
End Date:September 2021
Contact:Seattle Genetics Trial Information Support
Email:clinicaltrials@seagen.com
Phone:8663337436

Use our guide to learn which trials are right for you!

Open Label Phase 2 Study of Tisotumab Vedotin for Patients With Platinum-Resistant Ovarian Cancer With a Safety Run-in of a Dose-Dense Regimen

This trial will study tisotumab vedotin to find out what its side effects are and to see if
it works for platinum-resistant ovarian cancer (PROC). We will be testing different doses of
tisotumab vedotin that are given at different times. We will compare the side effects and
ability to treat tumors of these different doses and schedules. In this study, there will be
a safety run-in group of up to 12 patients that will look at a dose-dense treatment schedule.
In a dose-dense schedule, smaller doses are given more frequently. After the run-in period is
over, there will be two groups in the study. One group will get tisotumab vedotin once every
3 weeks (21 day cycles). The other group will get tisotumab vedotin once a week for 3 weeks
followed by 1 week off (28-day cycles).

The study objectives are to evaluate the safety, antitumor activity, and pharmacokinetics of
tisotumab vedotin (TV) administered every 3 weeks or on Days 1, 8, and 15 of every 4-week
cycle (dose-dense regimen) for patients with epithelial ovarian cancer, primary peritoneal
cancer, or fallopian tube cancer that has relapsed within 6 months of the completion of
platinum-based treatment. All patients must have platinum-resistant ovarian cancer (PROC) and
be eligible for single agent chemotherapy. Additionally, patients must have previously
received a bevacizumab-containing treatment regimen for ovarian cancer, if eligible.

Inclusion Criteria:

- Histologic documentation of epithelial ovarian cancer, primary peritoneal cancer, or
fallopian tube cancer

- If eligible, patients must have received previous treatment with a
bevacizumab-containing regimen for ovarian cancer.

- Safety run-in only: Patients with platinum-resistant ovarian cancer (PROC) who have
received up to 5 prior systemic treatment regimens for ovarian cancer

- Phase 2 only: Patients with PROC who have received at most 1 prior cytotoxic
chemotherapy regimen in the PROC setting

- Measureable disease according to RECIST v1.1 as assessed by the investigator

- An Eastern Cooperative Oncology Group (ECOG) Performance Status score of 0 or 1

- Life expectancy of at least 3 months

- Able to provide fresh tissue for biomarker analysis from a newly obtained core or
excisional biopsy of a tumor lesion. Some exceptions may apply, in which case archival
tissue will be used.

Exclusion Criteria:

- Primary platinum-refractory disease, defined as disease progression within 2 months of
completion of first line platinum-based therapy

- Patients with clinical symptoms or signs of gastrointestinal obstruction with the past
6 months or who currently require parenteral nutrition

- Hematological: Known past or current coagulation defects leading to an increased risk
of bleeding, diffuse alveolar hemorrhage from vasculitis, known bleeding diathesis,
ongoing major bleeding, or trauma with increased risk of life-threatening bleeding
within 8 weeks of trial entry

- Cardiovascular: Clinically significant cardiac disease including uncontrolled
hypertension, unstable angina, acute myocardial infarction with 6 months of screening,
serious cardiac arrhythmia requiring medication, medical history of congestive heart
failure, or medical history of decreased cardiac ejection fraction of <45%

- Ophthalmological: Active ocular surface disease at baseline or prior episode of
cicatricial conjunctivitis or Steven Johnson syndrome

- Prior treatment with MMAE-derived drugs

- Inflammatory bowel disease including Crohn's disease and ulcerative colitis

- Ongoing, acute, or chronic inflammatory skin disease

- Uncontrolled tumor-related pain

- Inflammatory lung disease requiring chronic medical therapy

- Grade 3 or higher pulmonary disease unrelated to underlying malignancy

- Uncontrolled pleural or pericardial effusions

- Grade >1 peripheral neuropathy

- Patients who are pregnant or breastfeeding
We found this trial at
6
sites
Columbus, Ohio
Principal Investigator: David O'Malley
Phone: 614-247-7793
?
mi
from
Columbus, OH
Click here to add this to my saved trials
12902 USF Magnolia Dr
Tampa, Florida 33612
(888) 663-3488
Principal Investigator: Hye Sook Chon
Phone: 813-745-4673
H. Lee Moffitt Cancer Center & Research Institute Moffitt Cancer Center in Tampa, Florida, has...
?
mi
from
Tampa, FL
Click here to add this to my saved trials
Dallas, Texas 75246
Principal Investigator: Carlos Becerra
Phone: 214-820-7537
?
mi
from
Dallas, TX
Click here to add this to my saved trials
Fort Collins, Colorado 80528
Principal Investigator: Steven Schuster
Phone: 970-297-6163
?
mi
from
Fort Collins, CO
Click here to add this to my saved trials
30 Prospect Ave
Hackensack, New Jersey 07601
(201) 996-2000
Principal Investigator: Donna McNamara
Phone: 551-996-8258
Hackensack University Medical Center Hackensack University Medical Center, part of the Hackensack University Health Network,...
?
mi
from
Hackensack, NJ
Click here to add this to my saved trials
The Woodlands, Texas 77380
Principal Investigator: Mary Crow
Phone: 713-703-2398
?
mi
from
The Woodlands, TX
Click here to add this to my saved trials